Wednesday, July 8, 2026

pharma · Advanced Cancer · Advanced Solid Tumors · TCRT

Alaunos Therapeutics

Alaunos Therapeutics is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker TCRT. Primary therapeutic focus areas include Advanced Cancer, Advanced Solid Tumors, Solid Tumors, Melanoma, Me

8030 El Rio St, Houston, Texas 77054, US HQ
10 Employees
Public company Type
TCRT · NYSE Ticker
Company details
Status
Public
HQ
8030 El Rio St, Houston, Texas 77054, US
Employees
10
Programs
34
Drugs
12
Patents
0
Clinical program

Ad-RTS-hIL-12 and Veledimex

Phase 2 · gene therapy · Breast Cancer Nos Metastatic Recurrent

Ad-RTS-hIL-12 and Veledimex for Breast Cancer Nos Metastatic Recurrent is a Phase 2 program (gene_therapy) at Alaunos Therapeutics with 1 ClinicalTrials.gov record(s).

← All Alaunos Therapeutics projects Phase 2 gene therapy terminated

Internal code ATI001-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Alaunos Therapeutics
Phase
Phase 2
Modality
gene_therapy
Indication
Breast Cancer Nos Metastatic Recurrent
Status
terminated
Trials
1

Clinical trials